Havla Joachim, Reeve Kelly, On Begum Irmak, Mansmann Ulrich, Held Ulrike
lnstitute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.
lnstitute of Clinical Neuroimmunology, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, Germany.
Neurol Res Pract. 2024 Sep 5;6(1):44. doi: 10.1186/s42466-024-00338-z.
As a chronic inflammatory disease of the central nervous system, multiple sclerosis (MS) is of great individual health and socio-economic significance. To date, there is no prognostic model that is used in routine clinical care to predict the very heterogeneous course of the disease. Despite several research groups working on different prognostic models using traditional statistics, machine learning and/or artificial intelligence approaches, the use of published models in clinical decision making is limited because of poor model performance, lack of transferability and/or lack of validated models. To provide a systematic overview, we conducted a "Cochrane review" that assessed 75 published prediction models using relevant checklists (CHARMS, PROBAST, TRIPOD). We have summarized the relevant points from this analysis here so that the use of prognostic models for therapy decisions in clinical routine can be successful in the future.
作为一种中枢神经系统的慢性炎症性疾病,多发性硬化症(MS)对个人健康和社会经济具有重大意义。迄今为止,尚无用于常规临床护理以预测该疾病高度异质性病程的预后模型。尽管有几个研究小组使用传统统计学、机器学习和/或人工智能方法致力于不同的预后模型,但由于模型性能不佳、缺乏可转移性和/或缺乏经过验证的模型,已发表模型在临床决策中的应用受到限制。为了提供系统的概述,我们进行了一项“Cochrane综述”,使用相关清单(CHARMS、PROBAST、TRIPOD)评估了75个已发表的预测模型。我们在此总结了该分析的相关要点,以便未来在临床常规中使用预后模型进行治疗决策能够取得成功。